July 23, 2019
Roche/Chugai Pharmaceutical’s PD-L1 inhibitor Tecentriq (atezolizumab) will come up for review by a key health ministry advisory panel on August 2 for the treatment of small cell lung cancer (SCLC). If cleared, it is expected to receive approval in September...read more